NCT00150462 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 7
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 48
- units
- Participants
- groups
- description
- Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG000
- title
- CFZ 1.2 mg/m²
- description
- Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG001
- title
- CFZ 2.4 mg/m²
- description
- Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG002
- title
- CFZ 4.0 mg/m²
- description
- Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG003
- title
- CFZ 6.0 mg/m²
- description
- Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG004
- title
- CFZ 8.4 mg/m²
- description
- Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG005
- title
- CFZ 11.0 mg/m²
- description
- Participants received carfilzomib 15.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG006
- title
- CFZ 15.0 mg/m²
- description
- Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG007
- title
- CFZ 20.0 mg/m²
- description
- Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG008
- title
- CFZ 27.0 mg/m²
- description
- Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
- id
- BG009
- title
- CFZ 20/27 mg/m²
- description
- Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).
- id
- BG010
- title
- CFZ 20/27 mg/m² + DEX
- description
- Total of all reporting groups
- id
- BG011
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 17.47
- value
- 62.5
- group Id
- BG001
- spread
- 4.80
- value
- 69.6
- group Id
- BG002
- spread
- 21.71
- value
- 55.3
- group Id
- BG003
- spread
- 6.20
- value
- 51.7
- group Id
- BG004
- spread
- 9.15
- value
- 61.6
- group Id
- BG005
- spread
- 3.76
- value
- 61.3
- group Id
- BG006
- spread
- 12.99
- value
- 50.3
- group Id
- BG007
- spread
- 11.99
- value
- 60.6
- group Id
- BG008
- spread
- 9.82
- value
- 67.6
- comment
- Not applicable for Part 2 groups
- group Id
- BG009
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 2 groups
- group Id
- BG010
- spread
- NA
- value
- NA
- group Id
- BG011
- spread
- 12.25
- value
- 60.6
- title
- Dose Escalation (Part 1)
- categories
- measurements
- comment
- Not applicable for Part 1 groups
- group Id
- BG000
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG001
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG002
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG003
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG004
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG005
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG006
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG007
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG008
- spread
- NA
- value
- NA
- group Id
- BG009
- spread
- 9.21
- value
- 66.3
- group Id
- BG010
- spread
- 13.57
- value
- 54.3
- group Id
- BG011
- spread
- 11.96
- value
- 61.9
- title
- Dose Expansion (Part 2)
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 22
- title
- Female
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 6
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 26
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 3
- title
- African American
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 42
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Hispanic
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 2
- title
- Native American
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 6
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 28
- title
- Multiple Myeloma
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 17
- title
- Non-Hodgkin's Lymphoma
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 2
- title
- Waldenstrom's Macroglobulinemia
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Hodgkin's Disease
- param Type
- NUMBER
- title
- Disease Diagnosis
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 7
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 48
- units
- Participants
- groups
- description
- Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG000
- title
- CFZ 1.2 mg/m²
- description
- Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG001
- title
- CFZ 2.4 mg/m²
- description
- Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG002
- title
- CFZ 4.0 mg/m²
- description
- Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG003
- title
- CFZ 6.0 mg/m²
- description
- Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG004
- title
- CFZ 8.4 mg/m²
- description
- Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG005
- title
- CFZ 11.0 mg/m²
- description
- Participants received carfilzomib 15.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG006
- title
- CFZ 15.0 mg/m²
- description
- Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG007
- title
- CFZ 20.0 mg/m²
- description
- Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
- id
- BG008
- title
- CFZ 27.0 mg/m²
- description
- Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
- id
- BG009
- title
- CFZ 20/27 mg/m²
- description
- Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).
- id
- BG010
- title
- CFZ 20/27 mg/m² + DEX
- description
- Total of all reporting groups
- id
- BG011
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 17.47
- value
- 62.5
- group Id
- BG001
- spread
- 4.80
- value
- 69.6
- group Id
- BG002
- spread
- 21.71
- value
- 55.3
- group Id
- BG003
- spread
- 6.20
- value
- 51.7
- group Id
- BG004
- spread
- 9.15
- value
- 61.6
- group Id
- BG005
- spread
- 3.76
- value
- 61.3
- group Id
- BG006
- spread
- 12.99
- value
- 50.3
- group Id
- BG007
- spread
- 11.99
- value
- 60.6
- group Id
- BG008
- spread
- 9.82
- value
- 67.6
- comment
- Not applicable for Part 2 groups
- group Id
- BG009
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 2 groups
- group Id
- BG010
- spread
- NA
- value
- NA
- group Id
- BG011
- spread
- 12.25
- value
- 60.6
- title
- Dose Escalation (Part 1)
- categories
- measurements
- comment
- Not applicable for Part 1 groups
- group Id
- BG000
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG001
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG002
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG003
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG004
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG005
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG006
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG007
- spread
- NA
- value
- NA
- comment
- Not applicable for Part 1 groups
- group Id
- BG008
- spread
- NA
- value
- NA
- group Id
- BG009
- spread
- 9.21
- value
- 66.3
- group Id
- BG010
- spread
- 13.57
- value
- 54.3
- group Id
- BG011
- spread
- 11.96
- value
- 61.9
- title
- Dose Expansion (Part 2)
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 22
- title
- Female
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 6
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 26
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 3
- title
- African American
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 6
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 42
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Hispanic
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 2
- title
- Native American
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 6
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 28
- title
- Multiple Myeloma
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 17
- title
- Non-Hodgkin's Lymphoma
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 2
- title
- Waldenstrom's Macroglobulinemia
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Hodgkin's Disease
- param Type
- NUMBER
- title
- Disease Diagnosis
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle